Numerical Simulation of Fiber Laser Operated in Passively QSwitched and Mode-Locked Regimes

The aim of this chapter is to highlight the role of simulation methods as tools for analysis of low and medium average power fiber laser operated in passively Q-switched and/or mode-locking regimes into the design of various applications such as materials micro-processing of sensor applications. The chapter’s purpose consists in making available to specialists in the field of lasers, electro-optics and even nano-photonics improved procedures for designing high-accuracy remote sensors dedicated to large range of laboratory, industrial and military applications. The reason that this chapter deals with passive optical Q-switching and mode-locking techniques tailored for fiber lasers is the high percentage of sensing devices operating in this regime. Numerical simulation results obtained for this class of laser emitters can be used for other types of lasers, such as optical fiber lasers. There are briefly presented the two main mathematical methods used to analyze solid laser oscillators in passive optical Q-switching regime: the coupled rate equations approach and the iterative approach. The validation of the presented numerical simulation methods is done by comparison with experimental results

Numerical Simulation Methods Applied at Fiber Grating Sensors Design

The paper presents the results obtained in simulation of fiber Bragg grating (FBG) and long-period grating (LPG) sensors and their applications. The optical properties of FBG and LPG are firstly analyzed and, consequently, the basics of simulation models are provided. Coupled-mode theory and the transfer matrix methods are the two techniques used for the simulation of FBG and LPG. The numerical simulations are performed for an improved design of these types of fiber sensors, designs dedicated to specified applications. The different FBG types, i.e. the normal, chirped, apodized, according to different laws and tilted cases, are analyzed. Also, various LPG configurations are numerically simulated. The two main categories of sensing applications, for temperature and for mechanical stress/strain evaluation, are simulated for each type of fiber grating sensor. The chapter is intended to be a synthesis of already obtained results to which some results of research in development are added

Resumption of pituitary and ovarian activity post-partum: endocrine and ultrasonic observations in bromocriptine-treated women

The resumption of pituitary and ovarian activity was investigated by hormonal measurements and ultrasound scanning in 45 healthy post-partum women who were treated with bromocriptine. Bromocriptine, 50 mg (Parlodel LAR) was administered within 24 h post-partum. Plasma luteinizing hormone, follicle stimulating hormone, oestradiol, progesterone and prolactin concentrations were measured repeatedly and correlated with ultrasound measurements. Forty-one of the 45 women completed the study. A prompt fall in prolactin levels to normal (non-pregnant) values was observed within 24 h post-partum. Hereafter, a rapid return of the normal menstrual cycle was observed. Endocrine evidence of ovulation was obtained in 19/41 women within 1 month post-partum. Ultrasound measurements started at day 10 and were repeated regularly in 40 women. Ultrasound evidence of ovulation was found in 25/40 women. Ultrasound findings appeared not to correspond with the hormonal measurements. It is concluded that the resumption of pituitary and ovarian secretory functions post-partum is not always paralleled by a concomitant recovery of normal follicular growth and ovulation. Application of a progesterone threshold to judge resumption of ovulation post-partum should be reconsidere

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly

<div><h3>Background</h3><p>The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage.</p> <h3>Objective</h3><p>We performed a meta-analysis to accurately assess the effect of octreotide on pituitary tumor shrinkage.</p> <h3>Data Sources</h3><p>A computerized Medline and Embase search was undertaken to identify potentially eligible studies.</p> <h3>Study Eligibility Criteria</h3><p>Eligibility criteria included treatment with octreotide, availability of numerical metrics on tumor shrinkage and clear definition of a clinically relevant reduction in tumor size. Primary endpoints included the proportion of patients with tumor shrinkage and mean percentage reduction in tumor volume.</p> <h3>Data Extraction and Analysis</h3><p>The electronic search identified 2202 articles. Of these, 41 studies fulfilling the eligibility criteria were selected for data extraction and analysis. In total, 1685 patients were included, ranging from 6 to 189 patients per trial. For the analysis of the effect of octreotide on pituitary tumor shrinkage a random effect model was used to account for differences in both effect size and sampling error.</p> <h3>Results</h3><p>Octreotide was shown to induce tumor shrinkage in 53.0% [95% CI: 45.0%–61.0%] of treated patients. In patients treated with the LAR formulation of octreotide, this increased to 66.0%, [95% CI: 57.0%–74.0%). In the nine studies in which tumor shrinkage was quantified, the overall weighted mean percentage reduction in tumor size was 37.4% [95% CI: 22.4%–52.4%], rising to 50.6% [95% CI: 42.7%–58.4%] with octreotide LAR.</p> <h3>Limitations</h3><p>Most trials examined were open-label and had no control group.</p> <h3>Conclusions</h3><p>Octreotide LAR induces clinically relevant tumor shrinkage in more than half of patients with acromegaly.</p> </div

Management of acromegaly in Latin America: expert panel recommendations

Although there are international guidelines orienting physicians on how to manage patients with acromegaly, such guidelines should be adapted for use in distinct regions of the world. A panel of neuroendocrinologists convened in Mexico City in August of 2007 to discuss specific considerations in Latin America. Of major discussion was the laboratory evaluation of acromegaly, which requires the use of appropriate tests and the adoption of local institutional standards. As a general rule to ensure diagnosis, the patient’s GH level during an oral glucose tolerance test and IGF-1 level should be evaluated. Furthermore, to guide treatment decisions, both GH and IGF-1 assessments are required. The treatment of patients with acromegaly in Latin America is influenced by local issues of cost, availability and expertise of pituitary neurosurgeons, which should dictate therapeutic choices. Such treatment has undergone profound changes because of the introduction of effective medical interventions that may be used after surgical debulking or as first-line medical therapy in selected cases. Surgical resection remains the mainstay of therapy for small pituitary adenomas (microadenomas), potentially resectable macroadenomas and invasive adenomas causing visual defects. Radiotherapy may be indicated in selected cases when no disease control is achieved despite optimal surgical debulking and medical therapy, when there is no access to somatostatin analogues, or when local issues of cost preclude other therapies. Since not all the diagnostic tools and treatment options are available in all Latin American countries, physicians need to adapt their clinical management decisions to the available local resources and therapeutic options

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review

Acromegaly is a rare disease with a multifaceted clinical presentation. In 90–95% of patients with acromegaly, the disease is caused by a growth hormone (GH)-secreting pituitary adenoma with elevated GH levels that ultimately induce excessive hepatic secretion of insulin-like growth factor-1 (IGF-1). Somatostatin receptor ligands (SRLs) are considered the standard medical choice for the treatment of acromegaly, and normalization of GH and IGF-1 is attainable with effective therapy. This review aims to summarize the literature relative to SRL dose escalation therapy in patients with acromegaly. A United States National Library of Medicine PubMed search of SRL’s was conducted using the following search terms: ((((LAR) OR ATG) OR octreotide) OR lanreotide Autogel) AND acromegaly. Related articles in non peer-reviewed journals were excluded. The rationale and benefits of SRL dose optimization therapy were investigated with emphasis on describing the clinical recognition, treatment, and management of patients with acromegaly. We found that dose escalation could provide additional biochemical control of acromegaly in patients who are inadequately controlled with conventional starting doses of octreotide LAR and lanreotide Autogel®. Furthermore, patients should routinely have their GH and IGF-1 levels closely monitored and their SRL dose increased or decreased thereafter according to individual response

The evolution of fetal protection policies

This article examines the evolution of fetal protection policies (FPPs) by detailing their historical legacy and a range of contemporary social forces that have contributed to their maintenance. It is based on a case study of the 1977 U.S. Department of Labor, Occupational Safety and Health Administration (OSHA) hearings to revise the industrial lead standard, the 1991 U.S. Supreme Court decision that such policies are unconstitutional ( United Auto Workers v. Johnson Controls , 1991), and the case law preceding that decision. A primary issue is the notion that women and fetuses are disproportionately susceptible to lead. This study reveals the ways in which this belief is framed, disputed, and appropriated by various parties to the fetal protection policy debate. Implications of this case study for family health policy are also discussed.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44656/1/10834_2006_Article_BF02353687.pd

BARTER-BASED TRADE – THE ENGINE OF THE ECONOMIC RECESSION

Through this paper I would like to identify the main reasons that encourage firms to make barters. I would also like to find out who are the more likely to do this exchange and what are the main objects or services which are the subject of barters. This kind of exchange was present in ancient economies like the ones of the egyptians or indians. Even though there was no currency, an account unit was present, generally gold. I am attracted by this subject because the barter economy didn`t disappeared totally when the currency based trading began growing. In my opinion, a healthy economy should have a strong currency economy, but the businesses should seek partners willing to make barters. This kind of trading makes both partners happy – they get what they want, they don`t have to pay any money and they reduce their stock. If all economic agents would understand the benefits of being a barter trade practitioner than the economic growth would appreciate faster. This research is a small incentive for business owners to grow their deals even more. It`s very likely that after gathering some knowledge and finding out all the benefits of barter trading more and more company owners would like to do swap goods for any kind of needed service or product. The working hypothesis is that respondents are aware and make barters in proportion of 80%